Human Neural Stem Cells Over-Expressing VEGF Provide Neuroprotection, Angiogenesis and Functional Recovery in Mouse Stroke Model by Lee, Hong J. et al.
Human Neural Stem Cells Over-Expressing VEGF Provide
Neuroprotection, Angiogenesis and Functional Recovery
in Mouse Stroke Model
Hong J. Lee
1,2,3, Kwang S. Kim
1,3, In H. Park
1, Seung U. Kim
1,3*
1Brain Disease Research Center, Ajou University School of Medicine, Suwon, Korea, 2College of Bioscience and Biotechnology, Korea University,
Seoul, Korea, 3Division of Neurology, Department of Medicine, University of British Columbia Hospital, University of British Columbia, Vancouver,
Canada
Background. Intracerebral hemorrhage (ICH) is a lethal stroke type. As mortality approaches 50%, and current medical therapy
against ICH shows only limited effectiveness, an alternative approach is required, such as stem cell-based cell therapy.
Previously we have shown that intravenously transplanted human neural stem cells (NSCs) selectively migrate to the brain and
induce behavioral recovery in rat ICH model, and that combined administration of NSCs and vascular endothelial growth factor
(VEGF) results in improved structural and functional outcome from cerebral ischemia. Methods and Findings. We postulated
that human NSCs overexpressing VEGF transplanted into cerebral cortex overlying ICH lesion could provide improved survival
of grafted NSCs, increased angiogenesis and behavioral recovery in mouse ICH model. ICH was induced in adult mice by
unilateral injection of bacterial collagenase into striatum. HB1.F3.VEGF human NSC line produced an amount of VEGF four
times higher than parental F3 cell line in vitro, and induced behavioral improvement and 2–3 fold increase in cell survival at
two weeks and eight weeks post-transplantation. Conclusions. Brain transplantation of F3 human NSCs over-expressing VEGF
near ICH lesion sites provided differentiation and survival of grafted human NSCs and renewed angiogenesis of host brain and
functional recovery of ICH animals. These results suggest a possible application of the human neural stem cell line, which is
genetically modified to over-express VEGF, as a therapeutic agent for ICH-stroke.
Citation: Lee HJ, Kim KS, Park IH, Kim SU (2007) Human Neural Stem Cells Over-Expressing VEGF Provide Neuroprotection, Angiogenesis and
Functional Recovery in Mouse Stroke Model. PLoS ONE 2(1): e156. doi:10.1371/journal.pone.0000156
INTRODUCTION
Intracerebral hemorrhage (ICH) represents at least 15% of all
strokes in the western population and a considerably higher
proportion at 50–60% in the oriental populations in Korea, Chin
and Japan [1,2]. ICH is a lethal stroke type, as mortality
approaches 50% and neurological disability in survivors is
common. Since medical therapy against ICH such as mechanical
removal of hematoma, prevention of edema formation by drugs,
and reduction of intracranial pressure, shows only limited
effectiveness, alternative approach is required such as stem cell-
based cell therapy [3,4].
Recent progresses in stem cell biology have opened up an
avenue to therapeutic strategies to replace lost neural cells by
transplantation of neural stem cells (NSCs) in CNS injury and
disease [5–7]. Previous studies have indicated that NSCs or neural
progenitor cells engrafted in animal models of stroke survive and
ameliorate neurological deficits in the animals [8–13]. Among
these studies, human neural progenitor cells isolated from fetal
brain have been transplanted into the brain of stroke animal
models and found to restore brain function [8,13]. This approach,
however, is not widely acceptable for stroke patients because of
moral, religious and logistic problems associated with the use of
human fetal tissues. In addition, primary human NSCs derived
from fetal tissues can be provided for only a limited time before
they undergo senescence, and it is difficult to secure sufficient
numbers and homogeneous populations of human NSCs from
fetal brain. These problems can be circumvented by the use of
stable, permanent cell lines of human NSCs.
Previously we have generated a clonal permanent human neural
stem cell line, HB1.F3 (F3), that had been immortalized via
a retroviral vector encoding v-myc oncogene [14,15], and this F3
human NSC line shows multipotent capacity to differentiate into
neurons and glial cells [15–17], ameliorate neurological deficits in
animal models of Parkinson disease [18], Huntington disease
[19,20] and lysosomal storage disease [21] following their trans-
plantation into the brain. In stroke animal models, intravenously
transplanted F3 human NSCs migrated selectively to the damaged
brain sites caused by ischemia [9–11] and ICH [12], differentiated
into neurons and astrocytes, and promoted functional recovery in
these animals. However, low survival rate of grafted F3 NSCs in
ischemia and ICH rats in the previous studies is a grave concern;
less than 50% of grafted NSCs survived in ICH mice at 2 weeks
post-transplantation.
One significant way to promote differentiation and survival of
transplanted NSCs is to modulate microenvironment in the
injured brain following ICH, and this might be accomplished by
supplying additional neurotrophic growth factors such as brain-
derived neurotrophic factor (BDNF), glial cell line-derived
neurotrophic factor (GDNF) or vascular endothelial growth factor
(VEGF) which are known to play key roles in proliferation,
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factors which could be used in combination with transplanted
NSCs to improve therapeutic efficiency of cellular transplantation.
VEGF is an angiogenetic growth factor acting as a potent mitogen
and survival factor specific to endothelial cells [22,23], and also
known for neuroprotective effect against ischemic injury [24–28].
Considering evidence of functional recovery in stroke animal
models following brain transplantation of human NSCs [9–12]
and VEGF treatment [24–28], we wished to investigate whether
the human NSCs overexpressing VEGF, by pairing clonal human
NSCs with VEGF gene can lead to the increased cell survival and
functional improvement in mouse ICH stroke model.
MATERIALS AND METHODS
Clonal human neural stem cell line
Telencephalon tissue from a 15 week gestational human fetal brain
was utilized to generate primary cell culture from which immortal-
ized cell lines of human neural stem cells (NSCs) were generated
using a retroviral vector encoding v-myc oncogene [14,15]. One of
the NSC clones, HB1.F3, expressed phenotypes specific for neural
stem cells including ABCG2 and nestin. Additionally, F3 cells
differentiated into neurons and expressed Na
+ current when cells
were transduced with NeuroD gene [16]. F3 NSCs were grown in
a serum-free medium (DM4) consisting of Dulbecco’s modified
Eagle medium with high glucose (DMEM) containing 10 mg/ml
insulin, 10 mg/ml transferrin, 30 nM sodium selenate, 50 nM
hydrocortisone, 0.3 nM triiodothyronine and 20 mg/ml gentami-
cin [29]. Recombinant human bFGF (10 ng/ml; PeproTech,
Rocky Hill, NJ) was supplemented to the DM4 during the routine
feeding. All chemicals except bFGF were obtained from Sigma
(St Louis, MO).
Transfection of VEGF gene into F3 NSCs
Plasmid pLPCX.VEGF containing the full length human VEGF
cDNA was used in the present study. PG13 mouse packaging cell
line was transfected with pLPCX.VEGF vector (Fig. 1A) using
LipofectAMINE (Invitrogen, Carlsbad, CA) and a stable PG13
cell line was selected using 10 mg/ml puromycin for 3 days.
Replication incompetent retroviral vector collected from
PG13.VEGF cells was used for transfection of F3 NSCs.
Puromycin-resistant F3.VEGF clones were isolated, screened,
and one of the clones F3.VEGF.D2 was expanded, and used for
the transplantation. Expression of VEGF in F3.VEGF.D2 cell line
was analyzed by RT-PCR, ELISA and laser-scanning confocal
microscope.
Immunocytochemistry
Immunocytochemical demonstration of VEGF protein in
F3.VEGF human NSCs was performed as described previously
[30]. F3.VEGF human NSCs plated on poly-L-lysine-coated Aclar
plastic coverslips (9 mm in diameter, SPL, Seoul, Korea) were
grown in DM4 serum-free medium supplemented with bFGF for
2–5 days, rinsed in PBS and fixed in cold acid alcohol (5% glacial
acetic acid in 95% ethanol) for 10 min at 220uC. Cultures were
incubated in blocking solution consisted of PBS containing 10%
normal goat serum and 3% Triton-X at room temperature (RT)
for 20 min, followed by primary antibody specific for human VEGF
(1:200, mouse monoclonal, R&D, Minneapolis, MN) for 24 hr at
4uC, then with Alexa Fluor 594-conjugated anti-mouse IgG
(Molecular Probe, Eugene, OR) for 1 hr at RT. Cells were
counterstained with 49, 6-diamino-2-phenylindole (DAPI, Sigma,
St Louis, MO) to identify cellular nuclei. Following immunostaining,
cells were mounted on glass slides using gelvatol and viewed under
an Olympus laser-scanning confocal microscope (Tokyo, Japan).
RT-PCR analysis
F3 and F3.VEGF human NSCs were collected by centrifugation
and total RNA was isolated using Trizol, according to manu-
facture’s protocol (Promega, Madison, WI). One mg of total RNA
was reverse-transcribed into first-strand cDNA using oligo-dT
Figure 1. A: The retroviral vector encoding VEGF (pLPCX.VEGF) used in the present study in the generation of HB1.F3, VEGF human neural stem cell
line. B: Gene expression of cell type-specific markers as studied by RT-PCR in F3 and F3.VEGF human neural stem cell lines. Both F3 and F3.VEGF
human neural stem cell lines express cell type specific markers NF-L, NF-M and NF-H, an astrocyte marker GFAP and VEGF, while they do not express
MBP, a cell type marker of oligodendrocytes.
doi:10.1371/journal.pone.0000156.g001
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transcriptase (Takara, Seoul, Korea) for 1 hr at 42uC,inactivated for
10 min at 95uC and cooled to 4uC. The cDNA was diluted to a final
volume of 25 ml, and a 2 ml aliquot was used in a PCR reaction
containing 16DNA polymerase buffer, 1.5 mM MgCl2, 0.2 mM
dNTPs,10 pmolprimers,2.5 unitsofTaq polymerase(Takara).The
cDNA was amplified using 30 PCR cycles and RT-PCR products
were separated electrophoretically on 1.2% agarose gel containing
ethidium bromide and visualized under UV light. The primers used
for the RT-PCR for nestin, NF-L, NF-M, NF-H, GFAP, MBP,
VEGF, and GAPDH (all human) are listed in Table 1.
Mouse ICH model
All experimental procedures were approved by the Animal Care
Committee of the Ajou University Hospital. ICH was induced by
stereotaxic, intrastriatal administration of bacterial collagenase
by previously described methods [12,31]. In brief, after an
intraperitoneal injection of 1% ketamine (30 mg/kg) and xylazine
hydrochloride (4 mg/kg), the mice were placed in a stereotaxic
frame (Kopf Instruments, Tujunga, CA). A burr hole was made,
and a 30-gauge needle was inserted through the burr hole into the
striatum (0.1 mm posterior, 4.0 mm ventral, and 2.0 mm lateral
to the bregma). ICH was induced by the administration of
collagenase type IV (1 ml saline containing 0.078 U, Sigma) over
a period of 5 min. After remaining in place for another 3 min, the
needle was gently removed. During the procedure, rectum
temperature was monitored and maintained at 3760.5uC
Brain transplantation
Experimental groups are group 1 (control): injection of vehicle/
PBS (2 ml, n=20); group 2: transplantation of F3 (2610
5/2 ml,
n=23); and group 3: transplantation of F3.VEGF (2610
5/2 ml,
n=27). At 7 days after ICH, F3 or F3.VEGF NSCs (2610
5 cells/
2 ml) were transplanted into ipsillateral striatum, 2 mm cranial to
the hemorrhagic lesion, calculated from bregma: 0.1 mm anterior
and 2.0 mm right lateral to the bregma and 2.0 mm ventral to the
cortical surface. In order to detect the grafted cells in host brain,
donor F3 and F3.VEGF human NSCs were infected with an
adenovirus vector encoding LacZ gene (pAV.LacZ) in vitro at 100
MOI (PU/cell) for 24 hr before transplantation.
Behavioral Testing
Behavioral testing was performed weekly with the rotarod and
modified limb placement tests, which were monitored by 2
individuals blinded to rat treatment status. In the rotarod test [12],
the rats were placed on the rotarod cylinder, and the time the
animals remained on the rotarod was measured. The speed was
slowly increased from 4 to 40 rpm within a period of 5 min. The
trial was ended if the animal fell off the rungs or gripped the device
and spun around for 2 consecutive revolutions. The animals were
trained for 3 days before stem cell transplantation. The maximum
duration (in seconds) on the device was recorded with 3 rotarod
measurements 1 day before ICH induction. Motor test data are
presented as percentages of the maximal duration compared with
the internal baseline control (before ICH).
The details of limb placement test have been described
previously [32]. Test was repeated 3 times and are scored in the
following manner: normal performance, 0 points; performance
with a delay (2 seconds) and/or incomplete, 1 point; no perfor-
mance, 2 points. A total of 9 points means maximal neurological
deficit, and 0 points means normal performance. Additionally, the
body weights of all animals were checked weekly for 8 weeks.
Histology and immunohistochemistry
At the end of behavioral testing, each animal was anesthetized and
perfused through the heart with cold saline followed by 4%
paraformaldehyde in 0.1 M phosphate buffer. The brains were
post-fixed in same fixative for 24 hr, followed with cryoprotection
in 30% sucrose for 24 hr and then 30 mm sections were prepared
on a cryostat. Three sections through the needle entry site, which
was identifiable on the brain surface, and sites 1.0 mm anterior
and 1.0 mm posterior to plane were processed for b-gal staining to
analyze the hemisphere area. These sections are representative of
the core of the ICH lesion.
The morphometric analyses involved computer-assisted hand
delineation of the area of the striatum, cerebral cortex, and
ventricles, as well as the whole hemisphere. Adjacent serial coronal
sections were processed for double immunofluorescence staining of
b-gal (1:400, mouse monoclonal, Sigma) and antibodies specific
for cell type specific markers. Antibodies specific for neurofilament
low molecular weight protein (NF-L, 1:1000, rabbit, Chemicon),
neurofilament high molecular weight protein (NF-H, 1:1000,
rabbit, Chemicon), microtubule associated protein-2 (MAP2,
1:500, rabbit, Chemicon), glial fibrillary acidic protein (GFAP,
1:200, rabbit, DAKO, Carpinteria, CA), von Willebrandt factor
(vWF, 1:200, rabbit, Ongogene, Cambridge, MA) and VEGF
(1:200, rabbit, Oncogene) were used for cell type identification of
neurons, astrocytes, and endothelial cells. For the identification of
grafted F3 and F3.VEGF human NSCs, a monoclonal antibodies
specific for human cell nuclear matrix antigen (HuNuA, 1:200,
Chemicon) and human mitochondria (HuMit, 1:200, Chemicon)
were utilized.
Brain sections were incubated in mixed solution of primary
antibodies overnight at 4uC as free floating sections, followed by
mixed secondary antibodies of Alexa Fluor 488-conjugated anti-
mouse IgG (1:400, Molecular Probe) and Alexa Fluor 594-
conjugated anti-rabbit IgG for 1 hr at RT. Negative control
sections from each animal were prepared for Immunohistochem-
ical staining in an identical manner except the primary antibodies
were omitted. Stained sections were then examined under an
Olympus laser confocal fluorescence microscope.
Table 1. Sequence of PCR primers
......................................................................
Gene Sequence
Nestin Sense: 59-CTCTGACCTGTCAGAAGAAT-39
Antisense: 59-GACGCTGACACTTACAGAAT-39
NF-L Sense: 59-TCCTACTACACCAGCCATGT-39
Antisense: 59-TCCCCAGCACCTTCAACTTT-39
NF-M Sense: 59-TGGGAAATGGCTCGTCATTT-39
Antisense: 59-CTTCATGGAAGCGGCCAATT-39
NF-H Sense: 59-CTGGACGCTGAGCTGAGGAA-39
Antisense: 59-CAGTCACTTCTTCAGTCACT-39
MBP Sense: 59-ACACGGGCATCCTTGACTCCATCGG-39
Antisense: 59-TCCGGAACCAGGTGGTTTTCAGCG-39
GFAP Sense: 59-GCAGAGATGATGGAGCTCAATGACC-39
Antisense: 59-GTTTCATCCTGGAGCTTCTGCCTCA-39
VEGF Sense: 59-GAAGTGGTGAAGTTCATGGATGTC-39
Antisense: 59-CGATCGTTCTGTATCAGTCTTTCC-39
GAPDH Sense: 59-CATGACCACAGTCCATGCCATCACT-39
Antisense: 59-TGAGGTCCACCACCCTGTTGCTGTA-39
doi:10.1371/journal.pone.0000156.t001
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Experimental animals used in the study are group 1 (control,
vehicle/PBS n=3), group 2 (F3, n=3) and group 3 (F3.VEGF,
n=3). Total number of human nuclear matrix antigen (HuNuA)-
positive F3 and F3.VEGF NSCs in the brain sections from ICH
animals was determined by stereological estimation. The sections
used for counting covered the entire striatum with hemorrhage
lesion and overlying cortex. This generally yielded six or seven
sections in a series. Sampling was done using the Computer-
assisted stereological toolbox system, version 2.1.4 (Olympus),
using an Olympus BX51 microscope, a motorized microscope
stage (Prior Scientific, Rockland, NY) run by an IBM compatible
computer, and a microcator (Heidenhain ND 281B, Schaumberg,
IL) connected to the stage and feeding the computer with the
distance information in the z-axis. The counting areas were
delineated at a 1.256 objective and generated counting areas of
1506150 mm. A counting frame (1612 mm
2) was placed randomly
on the first counting area and systemically moved through all
counting areas until the entire delineated area was sampled. Actual
counting was performed using a 1006 oil objective. Guard
volumes (4 mm from the top and 4–6 mm from the bottom of the
section) were excluded from both surfaces to avoid the problem of
lost caps, and only the profiles that came into focus within the
counting volume (with a depth of 10 mm) were counted. The
estimate of the total number of HuNuA-positive F3 and F3.VEGF
was calculated according to the optical fractionator’s formula [33].
ELISA assays for human VEGF
F3 and F3.VEGF NSCs were each incubated in medium
containing 3% fetal bovine serum for 24 h, and the supernatants
were collected, while plastic adherent cells were harvested after
a brief incubation in PBS containing 0.25% trypsin and 1 mM
EDTA. The cells were lysed in RIPA buffer (150 mM NaCl, 1%
Nonidet P-40, 0.5% deoxycholic acid, 0.1% SDS, 50 mM Tris,
pH 8.0) containing protease inhibitors, centrifuged at 12,000 rpm
for 10 min, and the supernatant was collected. Levels of VEGF in
culture supernatants and cell lysates were determined by an
ELISA kits specific for human VEGF (R&D System, Minneapolis,
MN). Protein concentration was estimated using the method of
Bradford [34] with bovine serum albumin as a standard.
ICH mice were sacrificed and decapitated (three groups of
seven each, total n=21) and brains were removed 2 and 8 weeks
post-transplantation. Brains were cut in 2 mm coronal sections,
frozen and stored at 280uC until the assay. Two-millimeter
diameter punches centered on each side of the substantia nigra
(SN) were taken according to the atlas of Paxinos and Franklin
[35]. Seven tissue samples were collected in each of the three
groups from both the ipsillateral and contralateral SN. The
collected samples were homogenized with lysis buffer (137 mM
NaCl, 20 mM Tris, pH 8.0, 1% NP40, 10% glycerol, 1 mM
PMSF, 10 mg/ml aprotinin, 1 mg/ml leupeptin and 0.5 mM
sodium vanadate), centrifugation at 12,000 rpm for 10 min and
the supernatants were used for ELISA assay.
Western blot analysis
ICH mice of 2 and 8 weeks post-transplantation were sacrificed
and decapitated (three groups of seven each, total n=21), brains
removed, left brain hemisphere containing hemorrhage lesion/cell
transplantation sites were dissected out and homogenized in 10
volumes of cold homogenization buffer (50 mM Tris, 120 mM
NaCl, pH 7.4) containing protease inhibitors and stored at
280uC. Protein extracts from brain tissue (20 mg) were separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Protein separation was performed using a 10% polyacrylamide
with 0.05% bis-acrylamide. Proteins were then transferred to
nitrocellulose, and the blots were probed with antibodies specific
for VEGF1(1:1000, Santa Cruz Science, Santa Cruz, CA),
VEGF2 (1:1000, Santa Cruz), caspase 3 (1000, Santa Cruz), Bax
(1:1000, Santa Cruz), Bcl-2 (1:1000, Santa Cruz), Bcl-xL (1:1000,
Santa Cruz), Akt1 (1:1000, Chemicon), PI3 kinase p85 and p110
(1:1000, Oncogene). PI3-kinases catalyze the synthesis of PI-4,5-
biphosphate, which regulates various processes including cell
proliferation, survival, membrane trafficking, and cytoskeletal
organization. PI3-kinase is a heterodymeric complex of an 85K
regulatory subunit and an 110K catalytic subunit. Secondary
antibodies (Amersham Chicago, IL) and a chemiluminescence kit
(Amersham) were used for immunodetection. Western blot analysis
was performed on samples from three separated experiments.
Microvessel count
To investigate the number of microvessels in the ICH brain
transplanted with F3 or F3.VEGF human NSCs, coronal brain
sections 2 mm anterior and 2 mm posterior from the needle track,
were chosen and processed for von Willebrand factor immunos-
taining. Brain sections were incubated in an antibody specific for
von Willebrandt factor (1:2000, rabiit polyclonal, Oncogene)
overnight at RT, followed by Alexa Fluor 594-conjugated anti-
rabbit IgG for 1 hr at RT. Number of microvessels in brain
sections was determined in a low-power magnification of 6100.
The number of microvessels was calculated as the mean of the
microvessels counts obtained from the three microscopic images.
TUNEL staining
Three groups of four mice (total n=12) were used in the study.
DNA fragmentation was detected by using TUNEL POD
(Terminal deoxynucleotidyl transferase-mediated d-UTP Nick
End Labeling Peroxidase) combined with nonisotopic digoxi-
genin-11dUTP and terminal transferase according to manufac-
turer’s instructions (Roche Molecular, Indianapolis, IN). Briefly,
brain sections were incubated with permeabilization solution
(0.1% TritonX-100 in 0.1% sodium citrate) on ice for 2 min, and
endogenous peroxidase activity was quenched with 0.3% hydro-
gen peroxide in methanol for 30 min at RT. After PBS wash,
brain sections were incubated with TUNEL reaction mixture for
30 min at 37uC, followed by TUNEL POD for 30 min at RT and
the reaction was visualized with DAB reaction.
Statistical analysis
Data are presented as means6SEM. The statistical significance
between group comparisons for behavioral data was determined
by one-way ANOVA and two-way ANOVA. P values ,0.001
were considered to be statistically significant.
RESULTS
Stable human neural stem line overexpressing VEGF
HB1.F3 human NSC line was infected with a retroviral vector
encoding human VEGF gene twice, clones resistant to puromycin
were selected, and then cloned again by limited dilution. The
morphology of selected cell line of F3.VEGF does not differ from
the parental F3 NSC line with bipolar- or multipolar-morphology
(Figs. 2A, C). Immunfluorescence study demonstrated that a small
number of parental F3 cells (Fig. 2B) and all the F3.VEGF cells are
strongly immunoreactive to VEGF antibody (Fig. 2D).
Results of RT-PCR analysis of mRNAs isolated from F3 and
F3.VEGF human NSCs are shown in Figure 1B. Transcripts for
Human Neural Stem Cells
PLoS ONE | www.plosone.org 4 January 2007 | Issue 1 | e156Figure 2. Immunofluorescence microscopy demonstrating production of VEGF in parental F3 human neural stem cell line (A, C) and F3.VEGF, the
human neural stem cell line overexpressing VEGF (B, D). Results from the ELISA assay for human VEGF indicate that the levels of VEGF in spent media
from F3.VEGF cell line are 5 times over those of F3 cell line (E). Levels of VEGF production in brain sections isolated from intracerebral hemorrhage
(ICH) mice grafted with F3 or F3.VEGF human neural stem cells (F). VEGF levels are significantly higher in the F3.VEGF-transplanted mice 2 weeks and
8 weeks post-transplantation as compared with ICH mice grafted with F3 cell line. *: P,0.001, **: P,0.05
doi:10.1371/journal.pone.0000156.g002
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(NF-L, NF-M and NF-H, cell type-specific markers for neurons),
glial fibrillary acidic protein (GFAP, a specific marker for
astrocytes), and VEGF are all expressed by both F3 and F3.VEGF
cell lines (Fig. 1B). However, transcript for MBP, structural protein
and a specific cell type specific marker for oligodendrocytes, was
not demonstrated.
Levels of VEGF in the supernatants of cultured F3 and
F3.VEGF cell lines are shown in Fig. 2E. ELISA analyses
indicated that human VEGF released by F3.VEGF NSCs in
culture media is 3.7-fold over the control F3 parental NSCs
at 1832.96107.3 pg/10
6 cells/day (mean6SEM) vs 490.86
36.3 pg/10
6 cells/day (p,0.001). VEGF levels in brain sections
prepared from ICH animals transplanted with F3.VEGF, F3 and
PBS at 2- and 8-weeks post-transplantation were also determined
by VEGF ELISA assay (Fig. 2F). Details of the results are
described in a section below (In Vivo Levels of VEGF Production
by NSC grafts).
VEGF expression in transplanted NSCs
At 7 days after transplantation, F3.VEGF NSCs doubly positive
for b-gal and VEGF were found in the hemorrhage core indicating
that that the F3.VEGF NSCs were able to migrate from the
original injection site to the hemorrhage core and border area,
survive and functionally express VEGF at the brain injury sites
(Figs. 3A–F). In addition, these F3.VEGF NSCs could migrate
long distance and found in further areas in corpus callosum and
hippocampal formation (data not shown).
Figure 3. Double immunofluorescence microscopy demonstrating b-gal+/VEGF+ F3 cells (A–C) and b-gal+/VEGF+ F3.VEGF cells (D–F) in the
hemorrhage core borders 8 weeks post-transplantation. A markedly higher number of b-gal+/VEGF+ cells were found in the brain region grafted with
F3.VEGF cells. Bar indicates 50 mm.
doi:10.1371/journal.pone.0000156.g003
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transplantation
Motor performance of ICH animals receiving PBS, F3 or
F3.VEGF NSCs was determined by the rotarod test and neurology
score (Figs. 4A, B). Animals receiving F3.VEGF NSCs were able to
remain on the rotarod column significantly longer time than those
receiving F3 NSCs (by two-way ANOVA, F=50.32, P,0.001),
while no behavioral recovery was noted in control animals
receiving PBS. ICH mice grafted with F3.VEGF NSCs showed
a significant improvement in motor performance from 8 days
post-transplantation onward and the improvement lasted for up to
8-weeks post-transplantation as compared with controls groups.
Significant differences in behavioral performance in F3.VEGF vs
F3 groups detected during the period of 3–9 weeks post-
transplantation (p=0.05).
Survival of transplanted F3 and F3.VEGF NSCs in ICH
brain
At 7 days after induction of experimental ICH, 2610
5/2 mlo fF 3
or F3.VEGF NSCs (both labeled by adeno-LacZ) were trans-
planted into ICH mouse cerebral cortex overlying hemorrhage
lesion site, 2 mm cranial to the hemorrhagic lesion. Total number
of LacZ-positive F3 and F3.VEGF NSCs in the brain sections
from ICH animals were determined by stereological estimation at
2- and 8-weeks post-transplantation. The results indicate that cell
survival at 2-weeks post-transplantations is 136,35062645 cells
(68.263.2% of the initial population of 200,000 cells) and at 8
weeks post-transplantation the number is 78,07862734 cells
(39.063.3% of the initial population of 200,000 cells) (Figs. 5A–
E) These results indicate that the survival rate of grafted F3.VEGF
NSCs in the brain of ICH animals is 68% at 2 weeks post-
transplantation and 39% at 8 weeks post-transplantation. In ICH
animals transplanted with F3 NSCs, the number of surviving cells
is 71,29762171 cells (35.6613.8% of the initial population of
200,000 cells) at 2-weeks post-transplantation and 27,67362175
cells (13.862.7% of the initial population of 200,000 cells) at
8-weeks (p,0.001). These results indicate that VEGF over-
expression in NSCs resulted in a 2-fold increase in cell survival
of transplanted NSCs at 2 weeks post-transplantation and a 3-fold
increase at 8 weeks post-transplantation. There was no sign of
tissue distortion or tumor formation in brain of ICH animals
grafted with F3 or F3.VEGF NSCs (data not shown).
Transplanted NSCs differentiate into neurons and
astrocytes
Following transplantation into ICH mouse cerebral cortex overlying
hemorrhage lesion site, b-gal+/LacZ+ human NSCs migrated
selectively to the hemorrhagic core and also located on the border of
the lesion and further away from the injection sites. We also found
b-gal-positive F3.VEGF NSCs to the other brain sites including
corpus callosum and hippocampus (Figs. 6A–D). A large number of
transplanted b-gal+ F3.VEGF cells (35–45%) differentiated into
NF-L+/NF-H+ (Figs. 6E–J) or MAP2+ (Figs. 6K–M) neurons in the
peri-hematomal sites. Similarly a large proportion of the trans-
planted b-gal+ F3.VEGF cells (55–65%) were GFAP+ astrocytes
(Figs. 6N–P). Many of the b-gal+/GFAP+ double-positive cells were
found along the border of hemorrhagic core. These results indicate
that a majority of grafted F3.VGEF cells differentiate into either
neurons or astrocytes in response to signals from the local micro-
environment provided by the hemorrhagic lesion.
F3.VEGF stimulates proliferation of host
microvessels
To determine if transplanted F3.VEGF NSCs promote pro-
liferation of host endothelial cells/microvessels in the lesion sites,
number of endothelial cells 8 weeks post-transplantation was
determined using von Willebrandt factor (vWF) immunostaining.
Results indicated that the number of vWF-positive microvessels in
the F3.VEGF group was significantly higher as compared with
those in the F3 and PBS groups (Figs. 7A–F). Count of vWF-
positive microvessels in ICH brain sections indicates that there is
3–4 fold increase in vWF-positive microvessels in the brain
receiving F3.VEGF cells as compared to the control F3 cells at 2
and 8 weeks post-transplantation (Figs. 7G, H).
TUNEL staining
A large number of TUNEL (in situ end-labeling of nuclear DNA
fragmentation)-positive cells were found in the brain sections in the
Figure 4. Behavioral improvement demonstrated in mice with in-
tracerebral hemorrhage (ICH) transplanted with F3 or F3.VEGF human
neural stem cell lines. A: Rotarod test. F3.VEGF-transplanted group
showed better performance than PBS controls or F3-transplanted group
from 8 days on, and these benefits continued up to 8 weeks post-
transplantation (P,0.001). B: In the modified limb placement test,
F3.VEGF-transplanted group showed better performance than PBS or
F3-transplanted group (P,0.001).
doi:10.1371/journal.pone.0000156.g004
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PLoS ONE | www.plosone.org 7 January 2007 | Issue 1 | e156Figure 5. Survival of grafted F3.VEGF human NSCs was demonstrated by immunofluorescence microscopy of human nuclear matrix antigen (HuNuA)/
DAPI (A/C-2 weeks, B/D-8 weeks post-transplantation). Number of surviving human NSCs expressing HuNuA (means6SE) in ICH mouse brain at 2 and
8 weeks post-transplantation (E). * P,0.001
doi:10.1371/journal.pone.0000156.g005
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PLoS ONE | www.plosone.org 8 January 2007 | Issue 1 | e156Figure 6. Good survival of F3.VEGF human neural stem cells pre-labeled with adeno-LacZ (b-gal) was found in hemorrhage core or lesion border of
experimental ICH mouse brain 8 weeks post-transplantation. A large number of LacZ+ F3.VEGF human neural stem cells were found to migrate to
contralateral side of hemisphere via corpus callosum (A). Higher magnification of migrating F3.VEGF cells is also shown (B–D). LacZ+ F3.VEGF cells
differentiate into neurons as shown by b-gal+/NF-L+ (E–G), b-gal+NF-H+ (H–J) and b-gal/MAP2 (K–M) and also into astrocytes as demonstrated by b-
gal+/GFAP+ staining (N–P). Bar indicates 50 mm.
doi:10.1371/journal.pone.0000156.g006
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hemorrhage core border areas, the number of TUNEL-positive
cells was much lower in the ICH animals receiving transplantation
of F3.VEGF cells than ICH animals receiving PBS or F3 cells
(Fig. 8A–D). The number of TUNEL-positive cells in ICH/
F3.VEGF brain was similar in the lateral or medial borders. This
pattern was similar in ICH mice grafted with F3 cells. Interest-
ingly, the number of TUNEL-positive cells bearing nuclear DNA
Figure 7. A promoted angiogenesis in hemorrhage lesion by transplanted F3 (A–C) and F3.VEGF (D–F) human NSCs was demonstrated by double
immunofluorescence staining of human motochondria (HuMit, green) and von Willebrandt factor (vWF, red). Number of microvessels
immunoreaction-positive for von Willebrandt factor is significantly increased in F3.VEGF group as compared with control F3 group. Bar indicates
50 mm. * P,0.001
doi:10.1371/journal.pone.0000156.g007
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hemorrhage core, which was in the vicinity of the F3.VEGF grafts,
but not in the lateral border, away from the NSC grafts.
In vivo levels of VEGF production by NSC grafts
VEGF levels in brain sections prepared from ICH animals
transplanted with F3.VEGF, F3 and PBS at 2- and 8-weeks post-
transplantation were determined by VEGF ELISA assay (Fig. 4A).
VEGF levels in F3.VEGF-transplanted brain loci were 156.96
18.6 pg/mg protein (2 weeks) and 138.5615.2 pg/mg proteins
(8 weeks), while in the brain sections of F3 grafted loci was
67.9620.0 pg/mg (2 weeks) and 46.269.5 pg/mg (8 weeks). In
PBS-injected ICH animals, VEGF contents were below the
detectable level of the VEGF ELISA assay. These results indicate
that F3.VEGF NSCs at the ICH lesion sites are capable of
producing markedly higher amount of VEGF than the parental F3
cells in the lesion sites and thus capable of providing neuropro-
tective and neoangiogenetic action in the ICH injury sites resulting
in improved behavioral outcome. VEGF levels in ICH animals
grafted with F3.VEGF, F3 or PBS were also determined by
Western blot analyses. ICH animals with F3.VEGF cell trans-
plantation showed higher levels of VEGF than animals receiving
F3 cells (Data not shown). These results agree closely with results
obtained with immunocytochemical VEGF staining (Fig. 3).
VEGF blocks apoptotic cell death
To understand the mechanisms underlying neuroprotecitive action
of VEGF in the ICH brain, we examined expression of several
apoptosis-related proteins including pro-apoptotic proteins caspase
3 and Bax, anti-apoptotic proteins Bcl-2 and Bcl-XL, and survival
Figure 8. At 8 weeks post-transplantation in the hemorrhage core border areas, the number of TUNEL (in situ end-labeling of nuclear DNA
fragmentation)-positive cells was highest in PBS-ICH control animals (A), while the number of TUNEL-positive cells is much lower in the ICH-F3 (B) or
ICH-F3.VEGF groups (C). Bar indicates 100 mm.
doi:10.1371/journal.pone.0000156.g008
Human Neural Stem Cells
PLoS ONE | www.plosone.org 11 January 2007 | Issue 1 | e156signal molecules p85, p110 and Akt1 using Western blot analyses.
The results showed that the expression of proapoptotic protein
caspase 3 and Bax increased in the ICH-PBS group, while in ICH
brain receiving-F3 and ICH-F3.VEGF group marked reduction in
their expression was found (Fig. 9). In converse to the levels of
proapoptotic proteins, levels of antiapoptotic proteins Bcl-2,
Bcl-XL and survival signal molecules p85, p110 and Akt1 in
ICH brain receiving F3 or F3.VEGF grafts were significantly
higher as compared with ICH-PBS control group (Fig. 9). These
results suggest that F3.VEGF provides neuroprotective effect via
down-regulation of expression in pro-apoptotic proteins while
production of anti-apoptotic proteins and cell survival promoting
molecules is up-regulated.
DISCUSSION
In the present study, an animal model of intracerebral hemorrhage
(ICH) was used to provide proof-of-principle that human NSCs
over-expressing growth factor VEGF can be transplanted in the
brain of animal models of neurological diseases, and produce
beneficial effects of functional recovery, increased angiogenesis in
the host brain and increased survival of grafted NSCs. We also
tested the hypothesis that the human NSCs could be used as
a novel carrier for the delivery of the VEGF gene, providing
neuroprotection in animals suffering from ICH injury. Our results
demonstrated that the F3 human NSCs transduced with VEGF
gene could survive well in the ICH animal brain and release
VEGF protein in the hemorrhagic brain injury sites following
transplantation.
In the present study, from as early as one day post-trans-
plantation to 8 weeks post-transplantation, F3.VEGF cells pro-
vided functional recovery as determined by rotarod test and limb
placement test and also induced an increased survival of trans-
planted NSCs, inhibition of apoptosis, and renewed angiogenesis
in the host brain. The present study demonstrates that VEGF
secreted from transplanted human NSCs promoted cell survival
pathways and blocked cell death in the ICH brain.
F3 NSCs overexpressing VEGF were able to survive much
better than parental F3 NSCs, so that there were a 2-fold increase
in cell survival of transplanted F3.VEGF cells at 2 weeks post-
transplantation and a 3-fold increase at 8 weeks, and a majority
of grafted F3.VGEF cells differentiated into either neurons or
astrocytes in response to signals from the local microenvironment.
In addition, the number of TUNEL-positive cells, neruons
undergoing apoptotic cell death, was much lower in the ICH
animals receiving F3.VEGF cells than in animals receiving PBS or
parental F3 cells. The number of von Willebrandt factor-positive
microvessels in ICH brain receiving F3.VEGF cells is 3–4 fold
higher as compared to the control F3-ICH brain. These results
indicate that F3.VEGF NSCs at the ICH lesion sites are capable of
producing markedly higher amount of VEGF than the parental F3
cells and thus providing neuroprotective and neoangiogenetic
action in the ICH injury sites resulting in improved behavioral
outcome.
The present results showed a marked reduction in expression of
proapoptotic proteins caspase 3 and Bax in ICH brain receiving
F3 or F3.VEGF cells, while their expression was found to increase
in control vehicle/PBS group. In converse to the levels of
proapoptotic proteins, levels of antiapoptotic proteins (Bcl-2 and
Bcl-xL) and survival signal molecules (p85, p110 and Akt1) in ICH
brain receiving F3 or F3.VEGF grafts were significantly higher as
compared with control ICH-PBS group. These results suggest that
F3.VEGF cells provide neuroprotective effect via down-regulation
of expression in pro-apoptotic proteins while production of anti-
apoptotic proteins and cell survival promoting molecules are
up-regulated. It is known that VEGF activates PI3-kinase-Akt
pathway via VEGF receptors. Akt, a serine2threonine protein
kinase, exerts antiapoptotic effects by preventing the release of
cytochrome c from mitochondria, by inactivating fork-head
transcription factors by which transcription of proapoptotic genes
is inhibited, by inducing transcription of the survival genes
regulated by NF-kB and CREB, and by phosphorylating and
inactivating the proapoptotic factors BAD and pro-caspase-9 [36–
38]. As demonstrated in the present study, VEGF is also beneficial
to the ICH-injured brain indirectly by promoting angiogeneis.
New vessel formation mediated by VEGF will improve blood
supply to the injured region, thereby efficiently providing oxygen
and nutrients to the degenerating and regenerating neurons in the
injured brain.
Previous studies have demonstrated that the VEGF treatment in
vivo and in vitro could provide protection against several forms of
neuronal injury independently of its angiogenic action. For
example, VEGF enhances the survival of mouse hippocampal
neurons subjected to in vitro ischemia [39], and glutamate or
N-methyl-D-aspartate (NMDA) excitotoxicity [40,41]. In a middle
cerebral artery (MCA) occlusion ischemia model, VEGF was
found to induce proliferation and survival of endothelial cells
under the ischemic injury [42]. Several previous studies have
reported that the infusion of VEGF into ischemia lesioned brain
produced somewhat inconsistent results [24–28,43]. In earlier
studies, VEGF induces blood-brain barrier (BBB) break down and
vascular leakage resulting in brain edema [25,43]. Similarly,
application of adenovirus-VEGF in the ischemic brain caused an
inflammatory response and BBB disruption [44]. In contrast,
application of exogenous VEGF has shown direct neuroprotection
Figure 9. Western blot analysis of apoptosis-related proteins, including
proapoptotic proteins, (caspase 3 and Bax), antiapoptotic proteins (Bcl-
2 and Bcl-XL), and cell survival signal molecules (PI3-kinase p85, PI3
kinase p110 and Akt1) in ICH brains receiving transplantationof F3 and
F3.VEGF human neural stem cells. A significantly decreased expression
of caspase 3 and bax is found in ICH-F3.VEGF group at 2 and 8 weeks
post-transplantation. In ICH animals receiving F3.VEGF grafts, the
expression of antiapototic proteins and signal molecules Bcl-2, Bcl-XL,
PI3-K p85, PI3-K p110 and Akt1 is markedly increased.
doi:10.1371/journal.pone.0000156.g009
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[24,26–28]. These differences in outcome could be attributed to
different route of VEGF administration, concentrations and amount
of VEGF used, and expression of VEGF receptors [45]. In com-
parison with intracerebral or intracerebroventricular application of
exogenous VEGF as previous studies have reported, intracerebral
transplantation of human NSCs producing VEGF, as shown in this
study, is reproducible, provides a unique way to supply sufficient
amount of VEGF continuously, produce neuroprotection, and
stimulate neurogenesis and angiogenesis in the ICH brain.
The neuroprotective effect of VEGF in ICH mice is mediated
by VEGF’s ability to promote neuronal survival by active inhibi-
tion of apoptosis, which is accomplished by inhibiting the
expression of pro-apoptotic factors as well as promoting the
expression of antiapoptotic factors [27,46]. PI3 kinase pathway,
activated by many survival factors, leads to the activation of Akt,
an important player in survival signaling pathways. Activated Akt
inhibits the pro-apoptotic factors Bad, caspase-9, GSK-3 and
FKHR by phosphorylation. Growth factors such as VEGF induce
anti-apoptotic BCl-2 family members that protect the integrity of
mitochondria, preventing cytochrome C release and the sub-
sequent activation of caspase-9 and -3 [47–49]. A recent study has
shown that VEGF can also act on the neuronal microtubular
content, which is involved with growth, stability and maturation of
neurons [50]. Taken together, the present study demonstrates that
the transplanted F3.VEGF human NSCs provide neuroprotective
effect in ICH mouse brain via downregulation of pro-apoptotic
protein expression and upregulation of anti-apoptotic proteins and
cell survival promoting molecules.
In conclusion, our study suggests that in the ICH mouse brain,
transplantation of VEGF-producing human NSCs (a) provides
neuroprotection against hemorrhage injury, (b) improves func-
tional recovery in ICH animals, and (c) stimulates angiogenesis in
ICH lesion and border areas. These results suggest a possible
application of the human neural stem cell line which is genetically
modified to overexpress VEGF as a therapeutic agent for ICH-
stroke.
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